Pfizer Pipeline Bet to Show If Drugmaker Has Blockbuster

Pfizer Inc.’s Chief Executive Officer Ian Read will find out in the next six months whether his plan to shed units and focus on new drugs will pay off, with three top products awaiting approval or key data.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.